Veradermics files S-1 to register 16.8 million resale shares from PIPE investors and insiders

Veradermics, Incorporated filed a Form S-1 with the SEC on August 7, 2026, registering the resale of up to 16,772,058 shares of common stock plus 300,000 shares issuable upon exercise of pre-funded warrants. The company is not offering any shares itself under this prospectus and will not receive proceeds from the resale, except for amounts collected if the pre-funded warrants are exercised for cash.¹

The shares stem partly from a private placement that closed in May 2026. Under a securities purchase agreement dated April 29, 2026, Veradermics sold pre-funded warrants for 300,000 shares to entities affiliated with Montanova Capital, formerly known as Suvretta Capital, at $99.99999 per warrant.¹ Gross proceeds from that placement were approximately $30.0 million before fees.¹

The filing also details the company's capital history. Veradermics raised money through Series A-4 preferred stock in April 2023, Series B preferred stock in November 2024, and Series C preferred stock in October 2025, with investors including entities affiliated with J.W. Childs Associates, Longitude Capital, SR One, Montanova Capital, Connecticut Innovations, and Citadel Multi-Strategy Equities, among others. Each series of preferred stock converted into common stock immediately before the company's IPO, adjusted for a 1-for-10.067 reverse stock split effected on January 27, 2026.¹

The resale shares represent roughly 40.6% of Veradermics' total outstanding common stock as of June 30, 2026, assuming exercise of the pre-funded warrants.¹ The company's stock trades on the New York Stock Exchange under the ticker "MANE," and closed at $108.65 on August 6, 2026.¹

Veradermics describes itself as a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing therapeutics for aesthetic and dermatological conditions¹, with lead candidate VDPHL01, an oral treatment for pattern hair loss.